Replies to post #139122 on Biotech Values

[mcbio]

Was there discussion of the additional bioequivalence study on the recent webcast?

I don't recall specific discussion about that but I could have missed it. It was a relatively short presentation so I'll try and listen again if time permits.

[Bio_pete]

POZN - the additional trial was discussed during the 4th qtr CC. CEO wasn't concerned & it won't cause a delay in filing the NDA. The guys pretty straight forward so I tend to believe his statements.

[turtlepower]

POZN - I see that biopete already posted on this. Anyone interested in hearing what Plachetka said on this topic can go to the 9.50 mark.

http://edge.media-server.com/m/p/ic9vvaqq/lan/en